PBAC's latest decision on Plerixafor: Recommended with restriction (2013). Considered for In combination with G-CSF, for mobilisation of haematopoietic stem cells in patients with multiple myeloma or lymphoma requiring autologous stem cell transplantation, specifically in failed mobilisers or those undergoing rescue of failing mobilisation.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$200k/QALY
$15k/QALY–$200k/QALY · across 2 submissions
Submissions
4
first 2010
Submissions
4
2010 → 2013
Eligible population
Adult patients with multiple myeloma or lymphoma who require autologous stem cell transplantation and are either failed mobilisers (stem cell yield <2.0 × 10⁶ CD34+ cells/kg at previous attempt) or undergoing rescue of failing mobilisation (peripheral CD34+ cell count ≤10 cells/µL or Day 1 yield <1.0 × 10⁶ CD34+ cells/kg).
Therapy area
Haematology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Surrogate
Comparator
G-CSF in combination with chemotherapy (ifosfamide + carboplatin + etoposide for lymphoma; cyclophosphamide for multiple myeloma)
Economic model
CEA
ICER basis
Range aggregates 2 submissions (2011–2013) — not a single base case.
Submission history
Nov 2010: Recommended with restriction
Nov 2011: Not recommended — ICER $75k/QALY
Jul 2012: Not recommended
Nov 2013: Recommended with restriction · Authority Required — ICER $200k/QALY